Sublingual immunotherapy for allergic rhinitis and conjunctivitis

Immunotherapy

Volumn 5, Issue 3, 2013, Pages 257-264

  Passalacqua, Giovanni ^a   Garelli, Valentina ^a   Sclifò, Francesca ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

allergic rhinoconjunctivitis; efficacy; meta analysis; safety; SLIT; sublingual immunotherapy

Indexed keywords

BUDESONIDE; GRASS POLLEN EXTRACT; MONTELUKAST; PLACEBO;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; FOOD ALLERGY; HUMAN; MOUTH DISCOMFORT; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; RHINITIS; SUBLINGUAL IMMUNOTHERAPY;

ADMINISTRATION, SUBLINGUAL; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 84874603819     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.157     Document Type: Review

References (83)

1. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin. Allergy 16, 483-491 (1986).
2. Bernstein D, Wanner B, Borish L, Liss GM, Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 113, 1129-1136 (2001).
3. Aaronson DW, Gandhi TK, Incorrect allergy injections: allergists' experiences and recommendations for prevention. J. Allergy Clin. Immunol. 113, 1117-1121 (2004).
4. WHO Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Malling HJ (Eds). Allergy 53 (Suppl.), 1-33 (1998).
5. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; WHO. Allergic rhinits and its impact on asthma. J. Allergy Clin. Immunol. 108(Suppl. 5), S147-S334 (2001).
6. Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64 (Suppl. 91), 1-59 (2009).
7. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: other indications. Immunol. Allergy Clin. North Am. 31, 279-287 (2011).
8. Nelson H, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J. Allergy Clin. Immunol. 92, 229-236 (1993).
9. Guez S, Vatrinet C, Fadel R, André C. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double-blind placebo controlled study. Allergy 55, 369-375 (2000).
10. Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J. Allergy Clin. Immunol. 119, 892-898 (2007).
11. Okubo K, Gotoh M, Fujieda S et al. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol. Int. 57, 265-275 (2008).
12. de Bot CM, Moed H, Berger MY et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr. Allergy Immunol. 23, 150-158 (2012).
13. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int. Arch. Allergy Immunol. 157, 288-298 (2012).
14. Wilson DR, Torres L, Durham SR. Sublingual immunotherapy for allergic rhinitis. Allergy 60, 3-8 (2005).
15. Calamita Z, Saconato H, Bronhara Pelà A et al. Efficacy of sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 61, 1162-1172 (2006).
16. Penagos M, Passalacqua G, Compalati E et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 133, 599-609 (2008).
17. Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children. Meta analysis of randomized controlled trials. Ann. Allergy Asthma Immunol. 97, 141-148 (2006).
18. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64, 1570-1579 (2009).
19. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J. Allergy Clin. Immunol. 126(3), 558-566 (2010).
20. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 12, CD002893 (2010).
21. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst. Rev. 6(7), CD007685 (2011).
22. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann. Allergy Asthma Immunol. 102, 22-28 (2009).
23. Nieto A, Mazon A, Pamies R, Bruno M, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J. Allergy Clin. Immunol. 124, 157-161 (2009).
24. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117(4), 802-809 (2006).
25. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118(2), 434-440 (2006).
26. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120(6), 1338-1345 (2007).
27. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, De Beaumont O. Efficacy and safety of 5 grass pollen sublingual immunotherapy in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 123(1), 160-166.e3 (2009).
28. Ott H, Sieber J, Brehler R et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64, 179-186 (2009).
29. Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J. Allergy Clin. Immunol. 123, 167-173 (2009).
30. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J. Allergy Clin. Immunol. 127, 64-71 (2011).
31. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J. Allergy Clin. Immunol. 127, 72-80 (2011).
32. Canonica GW, Baena Cagnani C, Bousquet J et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62, 317-324 (2007).
33. Marogna M, Spadolini I, Massolo A et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann. Allergy Asthma Immunol. 102(1), 69-75 (2009).
34. Marogna M, Colombo F, Spadolini I et al. Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J. Invest. Allergol. Clin. Immunol. 20(2), 146-152 (2010).
35. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin. Exp. Allergy 26, 1253-1261 (1996).
36. Khinchi S, Poulsen LK, Carat F, André C, Malling HJ. Clinical efficacy of sublingual swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen. A double blind double dummy placebo controlled study. Allergy 59(1), 45-53 (2004).
37. Eifan AO, Akkoc T, Yildiz A et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin. Exp. Allergy 40(6), 922-932 (2010).
38. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J. Allergy Clin. Immunol. 130, 1097-1107 (2012).
39. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 117, 1021-1035 (2006).
40. Didier A, Worm M, Horak F et al. Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J. Allergy Clin. Immunol. 128, 559-566 (2011).
41. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin. Immunol. 125, 131-138 (2010).
42. Dunsky E ,Goldstein MF, Dvorin MJ, Belecanech G. Anaphylaxis due to sublingual immunotherapy. Allergy 61, 1235 (2006).
43. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 61, 1236 (2006).
44. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 62, 567-568 (2007).
45. Blazowki L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 63, 374 (2008).
46. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 64, 963-964 (2009).
47. Agostinis F, Tellarini L, Falagiani P, Canonica GW, Passalacqua G. Safety of SLIT in very young children. Allergy 59, 675-676 (2004).
48. Fiocchi A, Pajno G, La Grutta S et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. 95, 254-258 (2005).
49. Di Rienzo V, Minelli M, Musarra A et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy 35, 560-564 (2005).
50. Agostinis F, Foglia C, Landi M et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 63, 1637-1639 (2008).
51. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61, 181-184 (2006).
52. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing-a new treatment schedule. Int. Arch. Allergy Immunol. 140, 321-326 (2006).
53. Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen. Eur. Ann. Allergy Clin. Immunol. 41, 177-180 (2009).
54. Canonica GW, Passalacqua G. Disease modifying effect and economic implications of sublingual immunotherapy. J. Allergy Clin. Immunol. 127, 44-45 (2011).
55. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62, 943-948 (2007).
56. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 114, 851-857 (2004).
57. Marogna M, Tomassetti D, Bernasconi A et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 101, 206-211 (2008).
58. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J. Allergy Clin. Immunol. 126, 969-975 (2010).
59. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy 33, 206-210 (2003).
60. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.Laryngoscope 117, 965-969 (2007).
61. Senna G, Calderon M, Makatsori M, Ridolo E, Passalacqua G. An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 11, 375-380 (2011).
62. Pajno G, Caminiti L, Vita D et al. Direct comparison between continuous and co-seasonal regimen for sublingual immunotherapy in children with grass allergy. Pediatr. Allergy Immunol. 22, 803-807 (2011).
63. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 62, 958-961 (2007).
64. Lombardi C, Incorvaia C, Braga M, Senna G, Canonica GW, Passalacqua G. Administration regimens for sublingual immunotherapy: what do we know. Allergy 64, 849-854 (2009).
65. Sander I, Fleischer C, Meurer U et al. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy 64, 1486-1492 (2009).
66. Calderon M, Mösges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 65(4), 420-434 (2009).
67. Bousquet PJ, Brozek J, Bachert C et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 64(12), 1737-1745 (2009).
68. Bousquet J, Schünemann HJ, Bousquet PJ et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy 66, 765-774 (2011).
69. Casale TB, Canonica GW, Bousquet J et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J. Allergy Clin. Immunol. 124, 665-670 (2009).
70. Passalacqua G, Canonica GW. Specific immunotherapy in asthma. Efficacy and safety. Clin. Exp. Allergy 41, 1247-1255 (2011).
71. Passalacqua G, Canonica GW. Specific immunotherapy: beyond clinical scores. Ann. Allergy Asthma Immunol. 107(5), 401-406 (2011).
72. Enrique E, Pineda F, Malek T et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J. Allergy Clin. Immunol. 116, 1073-1079 (2005).
73. Fernández-Rivas M, Garrido Fernández S, Nadal JA et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64(6), 876-883 (2009).
74. Kim EH, Bird JA, Kulis M et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J. Allergy Clin. Immunol. 127, 640-646 (2011).
75. Passalacqua G, Landi M, Pajno G. Oral immunotherapy in cow milk allergy. Curr. Opin. Allergy Immunol. 12, 271-277 (2012).
76. Nettis E, Delle Donne P, Di Leo E et al. Latex immunotherapy: state of the art. Ann. Allergy Asthma Immunol. 109(3), 160-165 (2012).
77. Gastaminza G, Algorta J, Uriel O et al. Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients. Trials 9(12), 191 (2011).
78. Pajno GB, Caminiti L, Vita D et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 120, 164-170 (2007).
79. Severino M, Cortellini G, Bonadonna P et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. 122(1), 44-48 (2008).
80. Saint-Lu N, Tourdot S, Razafindratsita A et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64, 1003-1013 (2009).
81. O'Hehir RE, Sandrini A, Anderson GP, Rolland JM. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr. Med. Chem. 4, 2235-2244 (2007).
82. Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J. Allergy Clin. Immunol. 127, 865-872 (2011).
83. Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 66(6), 733-739 (2011).